title: Markers of hemostatic system activation in pulmonary embolism. Changes during and after cessation of anticoagulant treatment.
abstract: Plasma levels of prothrombin fragment 1+2 (Fl+2), thrombin-antithrombin complexes (TAT) and D-dimers were measured in 15 patients with pulmonary embolism during heparin therapy, oral anticoagulation, and after cessation of warfarin therapy. Each patient had a favorable outcome during anticoagulant therapy (3 months), but late venous thromboembolism occurred in six cases. The mean levels of the three markers were significantly increased on day 4 after the thrombotic event, and normalized during warfarin therapy. Nine months after the initial pulmonary embolism, mean levels of the three markers, as compared with a control population, were significantly higher in the patients with late recurrences, whereas only TAT were slightly higher in patients without recurrences as compared with controls. Only TAT levels were significantly higher in the patients with late recurrences than in those without late recurrences. Thus, the levels of the three markers 9 months after pulmonary embolism seem to be interesting to identify patients with high risk of recurrence and who might require longer anticoagulant treatment.
authors.affiliation: Department of Haematology, Laennec Hospital, Paris, France.
authors.forename: E
authors.initials: E
authors.lastname: de Raucourt
authors.forename: G
authors.initials: G
authors.lastname: Meyer
authors.forename: P
authors.initials: P
authors.lastname: Landais
authors.forename: Z
authors.initials: Z
authors.lastname: Gouaref
authors.forename: P
authors.initials: P
authors.lastname: Morinet
authors.forename: F
authors.initials: F
authors.lastname: Monge
authors.forename: H
authors.initials: H
authors.lastname: Sors
authors.forename: A M
authors.initials: AM
authors.lastname: Fischer
mesh_terms: D000328:Adult; D000368:Aged; D000925:Anticoagulants / Q000008:administration & dosage*; D000990:Antithrombin III / Q000378:metabolism*; D015415:Biomarkers; D005338:Fibrin Fibrinogen Degradation Products / Q000378:metabolism*; D006487:Hemostasis; D006801:Humans; D008875:Middle Aged; D010446:Peptide Fragments / Q000378:metabolism; D010447:Peptide Hydrolases / Q000378:metabolism*; D011516:Prothrombin / Q000378:metabolism*; D011655:Pulmonary Embolism / Q000097:blood* / Q000188:drug therapy* / Q000503:physiopathology
chemical_list: D000925:Anticoagulants; D015415:Biomarkers; D005338:Fibrin Fibrinogen Degradation Products; D010446:Peptide Fragments; C046193:antithrombin III-protease complex; C036309:fibrin fragment D; D000990:Antithrombin III; D011516:Prothrombin; D010447:Peptide Hydrolases